Richard Beasley, MD
Internal Medicine · Rapid City, SDNPI 1093785735
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (54.7%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 33 manufacturers reported payments, led by GSK at 30.1% of the total. Reporting peaked in 2020 at $8,249 and has fallen 90.6% since, to $772 in 2025. Among internal medicine clinicians in SD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 598 payments — averaging $42.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$8K
- Astellas Pharma US Inc$5K
- Pfizer$2K
- Viiv Healthcare Company$2K
- AstraZeneca$1K
- AbbVie$1K
- plus $7K from 27 others
Across 905 payments — averaging $5050.12 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$916K
- AbbVie$887K
- Sanofi US Services Inc.$687K
- E.r. Squibb & Sons, L.L.C.$547K
- Janssen Research & Development, LLC$535K
- AstraZeneca$195K
- plus $803K from 23 others
What the payments were for
- Speaking & faculty fees$13,86555%
- Travel & lodging$1,3815%
- Food & beverage$9,93839%
- Education$1721%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 52 | $7,643 |
| Astellas Pharma US Inc | 11 | $4,946 |
| Pfizer | 61 | $1,715 |
| Viiv Healthcare Company | 1 | $1,600 |
| AstraZeneca | 26 | $1,491 |
| AbbVie(2 entities) | 60 | $1,241 |
| Lilly USA, LLC | 74 | $1,012 |
| Amgen(2 entities) | 66 | $979 |
| Seqirus USA Inc | 1 | $875 |
| Novo Nordisk | 70 | $801 |
| Johnson & Johnson | 31 | $576 |
| Sanofi-aventis U.S. LLC | 11 | $397 |
| Merck | 28 | $309 |
| Boehringer Ingelheim | 26 | $284 |
| Bayer | 5 | $282 |
| Avanir Pharmaceuticals, Inc. | 6 | $279 |
| Takeda Pharmaceuticals U.S.A., Inc. | 29 | $186 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $163 |
| E.r. Squibb & Sons, L.L.C. | 8 | $124 |
| Exact Sciences | 5 | $82 |
| Daiichi Sankyo Inc. | 5 | $77 |
| Eisai Inc. | 4 | $57 |
| Novartis | 2 | $33 |
| Lundbeck LLC | 2 | $32 |
| Clarus Therapeutics Inc. | 2 | $30 |
| Alfasigma USA, Inc. | 2 | $27 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
| Hologic Sales And Service, LLC | 1 | $19 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| IBSA Pharma Inc. | 1 | $17 |
| Alkermes, Inc. | 1 | $17 |
| Vivus LLC | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$6,900
- Veozah$4,692
- FARXIGA$477
- SOLIQUA 100/33$250
- Kerendia$250
- TEZSPIRE$248
- XARELTO$233
- NUEDEXTA$227
- UBRELVY$125
- NURTEC ODT$125
- AREXVY$125
- AIRSUPRA$124
- AIMOVIG$110
- SYMBICORT$104
- BREZTRI AEROSPHERE$104
How this compares
$25,356 in reported general payments places this provider in the 95th percentile of 178 internal medicine providers in South Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 49 | $58,506 |
| OzempicSemaglutide | 35 | $55,733 |
| EliquisApixaban | 56 | $47,174 |
| JardianceEmpagliflozin | 36 | $32,337 |
| EntrestoSacubitril/Valsartan | 12 | $17,472 |
| XareltoRivaroxaban | 23 | $17,164 |
| Breo ElliptaFluticasone/Vilanterol | 24 | $12,356 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $10,951 |
| Armour ThyroidThyroid,pork | 62 | $5,667 |
| BrilintaTicagrelor | 12 | $5,138 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 11 | $4,956 |
| SynthroidLevothyroxine Sodium | 34 | $2,839 |
| Atorvastatin Calcium | 227 | $2,566 |
| Levothyroxine Sodium | 216 | $2,409 |
| Tamsulosin Hcl | 161 | $2,332 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $1,012 | $58,50649 claims |
| Novo NordiskOzempic | $801 | $55,73335 claims |
| PfizerEliquis | $1,715 | $47,17456 claims |
| Boehringer IngelheimJardiance | $284 | $32,33736 claims |
| GSKBreo Ellipta, Trelegy Ellipta, Anoro Ellipta | $7,643 | $28,26252 claims |
| NovartisEntresto | $33 | $17,47212 claims |
| Johnson & JohnsonXarelto | $576 | $17,16423 claims |
| AbbVieArmour Thyroid, Synthroid | $1,241 | $8,50696 claims |
| AstraZenecaBrilinta | $1,491 | $5,13812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 178 internal medicine providers in South Dakota.
Other internal medicine in Rapid City
- Jennifer MayRapid City$52K
- Issam TurkRapid City$14K
- David EvansRapid City$3K
- Eric ChowRapid City$1K
- Matthew WerpyRapid City$873
- Kenneth HartRapid City$372
- David EatonRapid City$357
- Shailesh ThapaRapid City$238
- Marisa MedinaRapid City$228
- Nnamdi NwafoRapid City$170
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.